FDA panel backs Pfizer drug for kidney cancer

December 7, 2011 in Medications

(AP) -- A panel of advisers to the Food and Drug Administration voted Wednesday that the benefits of a Pfizer kidney cancer drug outweigh its risks, according to a company spokeswoman.

The unanimous vote came despite FDA concerns that the drug's benefit may have been limited to a subset of patients previously treated with other .

The FDA's panel of 13 cancer experts backed the benefits of Pfizer's axitinib for kidney cancer patients who have not responded well to at least one other drug. The agency is not required to approve drugs backed by the panel, though it often does.

. is seeking FDA approval to market the drug for advanced , the most common type of kidney cancer. Studies submitted by the company showed patients on axitinib experienced two more months without their cancer worsening than patients taking , a drug from Bayer and Onyx Pharmaceuticals.

But in a scientific review published ahead of the meeting, FDA experts questioned whether the benefit, known as progression-free survival, was driven by other drugs used by some patients.

FDA scientists noted that the slowdown in cancer progression was mainly seen in patients who had already been treated with cytokines, a class of cancer medications that are no longer widely used in the U.S. and Europe. Patients taking a more common medication called sunitinib only experienced a month and a half without their cancer worsening.

The New York-based company studied its drug in 723 advanced kidney cancer patients from North America, Europe, Asia and elsewhere.

The FDA is expected to make a final decision on whether to approve the drug in the first quarter of next year.

The market for kidney cancer drugs has grown increasingly crowded in recent years, with six new drugs approved in the last six years, including Roche's Avastin and GlaxoSmithKline's Votrient. If approved, Pfizer's drug would only be second designated as a backup, or second-line, treatment after other drugs have been prescribed.

©2011 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

not rated yet  

Rank not rated yet
Related Stories
Relevant PhysicsForums posts

More news stories

Merck ends development of Parkinson's disease drug

(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.

Medications created May 23, 2013 | popularity 1 / 5 (1) | comments 0

J&J expects 10-plus new drug applications by 2017

(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...

Medications created May 23, 2013 | popularity 5 / 5 (1) | comments 0

Experts favor US approval of Merck sleeping pill (Update)

An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.

Medications created May 22, 2013 | popularity not rated yet | comments 0

Glaxo, US partnering to develop new antibiotics

GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.

Medications created May 22, 2013 | popularity not rated yet | comments 0

Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine

The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...

Medications created May 22, 2013 | popularity not rated yet | comments 0


Engineered cytomegalovirus protects monkeys from HIV equivalent

(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...

Researchers identify first drug targets in childhood genetic tumor disorder

Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...

Hormone levels may provide key to understanding psychological disorders in women

Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.

Going live: Immune cell activation in multiple sclerosis

Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...

Help at hand for people with schizophrenia

How can healthy people who hear voices help schizophrenics? Finding the answer for this is at the centre of research conducted at the University of Bergen.

Alzheimer's disease, the soft target of the euthanasia debate

(Medical Xpress)—The way Alzheimer's disease is portrayed by advocacy groups and the media is having undue influence on the euthanasia debate, according to a Deakin University nursing ethics professor.